Daniel Honore Lachance, M.D., is a clinical neuro-oncologist who leads the Section of Neuro-Oncology at Mayo Clinic. Dr. Lachance's research includes efforts to engage and recruit Mayo patients to participate in neuro-oncology research in collaboration with the Alliance for Clinical Trials in Oncology and the National Cancer Institute at the National Institutes of Health (NIH). He also participates in the development of clinical trials and in the Collaborative Ependymoma Research Network (CERN).
Dr. Lachance's recent focus has been as a collaborator in work to understand the genetic basis of brain tumor development, including projects with Robert B. Jenkins, M.D., Ph.D., in the Mayo Clinic Brain Cancer SPORE Grant and with Melissa Bondy, Ph.D., in the International Case Control Study of Malignant Glioma. To facilitate these interests, he has worked with the Mayo Clinic Enterprise Data Trust toward the development of databases that interact in real time.
Dr. Lachance holds an appointment in the Department of Laboratory Medicine and Pathology in the Neuroimmunology Laboratory, where he has a clinical and research interest in paraneoplastic neurological disorders.
- Clinical neurology. Dr. Lachance is working to identify and report novel observations, with the potential to clarify important aspects of certain conditions.
- Neuroimmunology. Dr. Lachance also serves as a consultant in a high-volume clinical neuroimmunology research practice. Studies contribute to understanding the nature of paraneoplastic and nonparaneoplastic autoimmunity.
- Clinical neuro-oncology. In addition to his role as co-director and principal investigator (PI) of the Clinical Research Core of the Brain Cancer SPORE Grant, Dr. Lachance is a CERN participant, the Mayo Clinic PI for A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab Combined With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (CheckMate 143), and an investigator in the NCI Quantitative Imaging Network (PI: Bradley J. Erickson, M.D., Ph.D.).
- Genetic epidemiology of glioma. Dr. Lachance also contributes to glioma international family and case-control studies and is an investigator on the NIH-funded investigation led by Jann N. Sarkaria, M.D., to understand the molecular basis of long-term survival in glioblastoma.
Significance to patient care
From novel insights into new or well-known diseases to helping understand the molecular categorization of glioma, the goal of Dr. Lachance's work in clinical neurology, neuroimmunology and neuro-oncology is to better understand the diseases and contribute to the development of precisely targeted clinical interventions for patients.
- Head, Section of Neuro-oncology, Mayo Clinic Department of Neurology
- Charles C. Shepard Science Award in assessment and epidemiology, Center for Disease Control and Prevention, 2011